Intelligent Autoimmune Disease Prevention and Treatment System
Legal Citation
Summary of the Inventive Concept
A synergistic system integrating AI, IoT, blockchain, and nanomaterials to diagnose, predict, and treat autoimmune diseases by targeting pathogenic age-associated B cells, providing personalized medicine and improving treatment outcomes.
Background and Problem Solved
The original patent addressed the limitations of current autoimmune disease treatments by targeting pathogenic age-associated B cells. However, it lacked a comprehensive approach to diagnose, predict, and treat autoimmune diseases. This new inventive concept addresses these limitations by integrating distinct technologies to provide a more effective and personalized solution.
Detailed Description of the Inventive Concept
The system consists of a machine learning module trained on a dataset of pathogenic age-associated B cell characteristics, a blockchain-based data storage module for secure storage of patient data, and IoT-enabled wearable devices for monitoring patient health metrics. The AI-powered personalized medicine analyzes the health metrics and provides treatment recommendations. The system also includes a nanomaterial-based delivery system for targeted delivery of nucleic acids encoding human DEF6 protein and human SWAP-70 protein to pathogenic age-associated B cells. Additionally, the system features an AI-powered diagnostic module for real-time monitoring of treatment efficacy and a blockchain-based simulation platform for validating novel therapeutic targets.
Novelty and Inventive Step
The new claims introduce a synergistic combination of AI, IoT, blockchain, and nanomaterials, which is novel and non-obvious compared to the original patent. The integration of these distinct technologies provides a more comprehensive and effective solution for autoimmune disease diagnosis, prediction, and treatment.
Alternative Embodiments and Variations
Alternative embodiments include using different machine learning algorithms, varying the type of IoT-enabled devices, or incorporating additional technologies such as robotics or 3D printing. Variations of the system could be tailored to specific autoimmune diseases or patient populations, further expanding its applicability.
Potential Commercial Applications and Market
The Intelligent Autoimmune Disease Prevention and Treatment System has significant commercial potential in the healthcare industry, particularly in the fields of personalized medicine, precision health, and digital therapeutics. The system could be marketed to pharmaceutical companies, healthcare providers, and medical research institutions, offering a competitive advantage in autoimmune disease diagnosis and treatment.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Biomedical engineering, immunology, and computational medicine with expertise in autoimmune disease treatment, machine learning, and targeted therapeutic delivery systems
Person of Ordinary Skill (PHOSITA) Profile
A skilled practitioner with advanced degrees in biomedical engineering or immunology, proficient in AI/machine learning techniques, familiar with targeted drug delivery methods, and experienced in developing personalized medical technologies
Obviousness Rationale
A PHOSITA would recognize that integrating AI, IoT, and blockchain technologies with the existing targeted nucleic acid therapy for autoimmune diseases represents a predictable extension of known personalized medicine approaches. The combination of computational analysis, targeted delivery, and patient monitoring follows established paradigms in precision medicine. The technical elements disclosed in the PTD represent incremental improvements that would be obvious to a skilled practitioner seeking to enhance autoimmune disease treatment strategies.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,563 |
|---|---|
| Title | Inhibition of expansion and function of pathogenic age-associated B cells and use for the prevention and treatment of autoimmune disease |
| Assignee(s) | NEW YORK SOCIETY FOR THE RELIEF OF THE RUPTURED AND CRIPPLED, MAINTAINING THE HOSPITAL FOR SPECIAL SURGERY |